Enzymlogic receives the EIC Accelerator Seal of Excellence, a quality label that identifies companies with high quality project proposals under the European Union’s research and innovation program “Horizon 2020”.
The EIC Accelerator is a funding instrument, designed for deep-tech companies and start-ups, which invests in radically new ideas to expedite rolling out of marketable innovation solutions.
Notoriously known as being one of the most competitive and largest public funding programs in the European Union, from the over 4000 proposals from 21 countries submitted in 2021 only 2% were selected for funding.
At the end of the year, Enzymlogic’s project “KINETICfinder®: changing the way medicines are discovered” was evaluated by an international panel including business angels, venture capitalists and experts from innovation hubs. Enzymlogic’s proposal succeeded in receiving a very high evaluation score and the prestigious EIC AcceleratorSeal of Excellence.
The certificate recognizes the potential of our technology to disrupt the pharmaceutical industry, decreasing the span of the drug discovery process and our capacity of reaching new markets beyond EU.
Enzymlogic is a world leader in kinetic profiling of compounds to facilitate drug discovery.
As experts in the generation and interpretation of kinetic data, we pride ourselves on a proven track record of successful partnerships with worldwide organizations of all sizes, supporting them on a routine basis during the early phases of drug discovery.
We focus on the Hit to Lead (H2L) and Lead Optimization (LO) stages of drug discovery where our optimized kinetic profiling assays identify compounds with therapeutic potential that merit further progression into clinical trials.